Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance.
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace...
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.”
